NCT01923636View on ClinicalTrials.gov

Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero

NACompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

September 9, 2013

Primary Completion Date

January 30, 2021

Study Completion Date

May 16, 2022

Conditions
Congenital Cytomegalovirus Infection
Interventions
OTHER

detection of CMV

Clinical, radiological and laboratory (virological and immunological) standardized reports

Trial Locations (1)

75015

Hôpital Necker Enfants Malades, Paris

All Listed Sponsors
collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01923636 - Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero | Biotech Hunter | Biotech Hunter